Nwam LLC Purchases New Stake in Insmed Incorporated (NASDAQ:INSM)

Nwam LLC purchased a new stake in Insmed Incorporated (NASDAQ:INSM) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 36,096 shares of the biopharmaceutical company’s stock, valued at approximately $2,492,000.

Other hedge funds have also added to or reduced their stakes in the company. Jennison Associates LLC boosted its holdings in Insmed by 0.6% in the fourth quarter. Jennison Associates LLC now owns 773,813 shares of the biopharmaceutical company’s stock valued at $53,424,000 after acquiring an additional 4,560 shares during the last quarter. Capital CS Group LLC bought a new position in Insmed during the fourth quarter worth about $586,000. Orion Portfolio Solutions LLC boosted its holdings in Insmed by 48.5% during the third quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company’s stock worth $2,050,000 after buying an additional 9,170 shares during the last quarter. Ally Bridge Group NY LLC boosted its holdings in Insmed by 16.9% during the third quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company’s stock worth $11,011,000 after buying an additional 21,833 shares during the last quarter. Finally, TimesSquare Capital Management LLC bought a new position in Insmed during the third quarter worth about $35,322,000.

Insider Transactions at Insmed

In other Insmed news, CFO Sara Bonstein sold 18,322 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $80.31, for a total value of $1,471,439.82. Following the completion of the transaction, the chief financial officer now owns 118,863 shares of the company’s stock, valued at $9,545,887.53. This represents a 13.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lewis sold 18,750 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the completion of the transaction, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at approximately $27,079,091.58. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 532,207 shares of company stock valued at $41,400,465. Corporate insiders own 4.60% of the company’s stock.

Insmed Stock Performance

NASDAQ:INSM opened at $79.05 on Friday. The stock has a fifty day moving average price of $74.66 and a 200-day moving average price of $73.73. The company has a market cap of $14.31 billion, a price-to-earnings ratio of -14.14 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. As a group, equities analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Royal Bank of Canada assumed coverage on Insmed in a report on Tuesday. They set an “outperform” rating and a $100.00 target price on the stock. Truist Financial raised their target price on Insmed from $105.00 to $108.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Morgan Stanley lifted their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. Stifel Nicolaus cut their price objective on Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Finally, Wells Fargo & Company lifted their price objective on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $91.60.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.